United States - English - NLM (National Library of Medicine)

american health packaging - oxandrolone (unii: 7h6tm3ct4l) (oxandrolone - unii:7h6tm3ct4l) - oxandrolone 2.5 mg - oxandrolone is indicated as adjunctive therapy to offset the protein catabolism associated with prolonged administration of corticosteroids, and for the relief of the bone pain frequently accompanying osteoporosis (see dosage and administration ). oxandrolone is classified as a controlled substance under the anabolic steroids control act of 1990 and has been assigned to schedule iii (non-narcotic). - known or suspected carcinoma of the prostate or the male breast. - carcinoma of the breast in females with hypercalcemia (androgenic anabolic steroids may stimulate osteolytic bone resorption). - pregnancy, because of possible masculinization of the fetus. oxandrolone has been shown to cause embryotoxicity, fetotoxicity, infertility, and masculinization of female animal offspring when given in doses 9 times the human dose. - nephrosis, the nephrotic phase of nephritis. - hypercalcemia.

United States - English - NLM (National Library of Medicine)

upsher-smith laboratories, llc - oxandrolone (unii: 7h6tm3ct4l) (oxandrolone - unii:7h6tm3ct4l) - oxandrolone 2.5 mg - oxandrolone tablets, usp are indicated as adjunctive therapy to promote weight gain after weight loss following extensive surgery, chronic infections, or severe trauma, and in some patients who without definite pathophysiologic reasons fail to gain or to maintain normal weight, to offset the protein catabolism associated with prolonged administration of corticosteroids, and for the relief of the bone pain frequently accompanying osteoporosis (see dosage and administration ). oxandrolone is classified as a controlled substance under the anabolic steroids control act of 1990 and has been assigned to schedule iii (non-narcotic). - known or suspected carcinoma of the prostate or the male breast. - carcinoma of the breast in females with hypercalcemia (androgenic anabolic steroids may stimulate osteolytic bone resorption). - pregnancy, because of possible masculinization of the fetus. oxandrolone has been shown to cause embryotoxicity, fetotoxicity, infertility, and masculinization of female animal offspring when

United States - English - NLM (National Library of Medicine)

par pharmaceutical, inc. - oxandrolone (unii: 7h6tm3ct4l) (oxandrolone - unii:7h6tm3ct4l) - oxandrolone 2.5 mg - oxandrolone is indicated as adjunctive therapy to offset the protein catabolism associated with prolonged administration of corticosteroids, and for the relief of the bone pain frequently accompanying osteoporosis (see dosage and administration ). oxandrolone is classified as a controlled substance under the anabolic steroids control act of 1990 and has been assigned to schedule iii (non-narcotic). - known or suspected carcinoma of the prostate or the male breast. - carcinoma of the breast in females with hypercalcemia (androgenic anabolic steroids may stimulate osteolytic bone resorption). - pregnancy, because of possible masculinization of the fetus. oxandrolone has been shown to cause embryotoxicity, fetotoxicity, infertility, and masculinization of female animal offspring when given in doses 9 times the human dose. - nephrosis, the nephrotic phase of nephritis. - hypercalcemia.

United States - English - NLM (National Library of Medicine)

upsher-smith laboratories, llc - oxandrolone (unii: 7h6tm3ct4l) (oxandrolone - unii:7h6tm3ct4l) - oxandrolone 10 mg - oxandrolone tablets, usp are indicated as adjunctive therapy to promote weight gain after weight loss following extensive surgery, chronic infections, or severe trauma, and in some patients who without definite pathophysiologic reasons fail to gain or to maintain normal weight, to offset the protein catabolism associated with prolonged administration of corticosteroids, and for the relief of the bone pain frequently accompanying osteoporosis (see dosage and administration ). oxandrolone is classified as a controlled substance under the anabolic steroids control act of 1990 and has been assigned to schedule iii (non-narcotic). - known or suspected carcinoma of the prostate or the male breast. - carcinoma of the breast in females with hypercalcemia (androgenic anabolic steroids may stimulate osteolytic bone resorption). - pregnancy, because of possible masculinization of the fetus. oxandrolone has been shown to cause embryotoxicity, fetotoxicity, infertility, and masculinization of female animal offspring when

United States - English - NLM (National Library of Medicine)

savient pharmaceuticals, inc. - oxandrolone (unii: 7h6tm3ct4l) (oxandrolone - unii:7h6tm3ct4l) - tablet - 2.5 mg - oxandrin is indicated as adjunctive therapy to promote weight gain after weight loss following extensive surgery, chronic infections, or severe trauma, and in some patients who without definite pathophysiologic reasons fail to gain or to maintain normal weight, to offset the protein catabolism associated with prolonged administration of corticosteroids, and for the relief of the bone pain frequently accompanying osteoporosis (see dosage and administration). oxandrolone is classified as a controlled substance under the anabolic steroids control act of 1990 and has been assigned to schedule iii (non-narcotic). - known or suspected carcinoma of the prostate or the male breast. - carcinoma of the breast in females with hypercalcemia (androgenic anabolic steroids may stimulate osteolytic bone resorption). - pregnancy, because of possible masculinization of the fetus. oxandrin has been shown to cause embryotoxicity, fetotoxicity, infertility, and masculinization of female animal offspring when given in doses 9 time

Australia - English - Department of Health (Therapeutic Goods Administration)

xand innovations pty ltd -

Australia - English - Department of Health (Therapeutic Goods Administration)

xand innovations pty ltd -

Australia - English - Department of Health (Therapeutic Goods Administration)

xand innovations pty ltd -

Australia - English - Department of Health (Therapeutic Goods Administration)

xand innovations pty ltd -

Australia - English - Department of Health (Therapeutic Goods Administration)

xand innovations pty ltd - 37240 - compress, hot/cold pack, reusable - washable reusable face mask with cold packs to be applied to the face for compression and cold therapy after oral surgery procedures. the cold packs deliver a mild cold to relieve pain, bruising and swelling.